199 related articles for article (PubMed ID: 23155339)
1. Cost of treating chronic hepatitis B: comparison of current treatment guidelines.
Robotin M; Patton Y; Kansil M; Penman A; George J
World J Gastroenterol; 2012 Nov; 18(42):6106-13. PubMed ID: 23155339
[TBL] [Abstract][Full Text] [Related]
2. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
Lacey LF; Gane E
J Viral Hepat; 2007 Nov; 14(11):751-66. PubMed ID: 17927611
[TBL] [Abstract][Full Text] [Related]
5. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.
Crowley S; Tognarini D; Desmond P; Lees M; Saal G
J Gastroenterol Hepatol; 2002 Feb; 17(2):153-64. PubMed ID: 11966945
[TBL] [Abstract][Full Text] [Related]
6. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of screening immigrants for hepatitis B.
Wong WW; Woo G; Jenny Heathcote E; Krahn M
Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Dakin H; Sherman M; Fung S; Fidler C; Bentley A
Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
[TBL] [Abstract][Full Text] [Related]
9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
10. Reimbursement policies in the Asia-Pacific for chronic hepatitis B.
Lim SG; Amarapurkar DN; Chan HL; Crawford DH; Gane EJ; Han KH; Ahn SH; Jafri W; Jia J; Kao JH; Lesmana LA; Lesmana CR; Mohamed R; Phiet PH; Piratvisuth T; Sarin SK; Sollarno JD; Eguchi Y; Mahtab MA; Lee KH
Hepatol Int; 2015 Jan; 9(1):43-51. PubMed ID: 25788378
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Arnold E; Yuan Y; Iloeje U; Cook G
Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B.
Kim HL; Kim GA; Park JA; Kang HR; Lee EK; Lim YS
Gut; 2021 Nov; 70(11):2172-2182. PubMed ID: 33239344
[TBL] [Abstract][Full Text] [Related]
13. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B.
Oyagüez I; Buti M; Brosa M; Rueda M; Casado MA
Ann Hepatol; 2017; 16(3):358-365. PubMed ID: 28425405
[TBL] [Abstract][Full Text] [Related]
15. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.
Spackman DE; Veenstra DL
Pharmacoeconomics; 2008; 26(11):937-49. PubMed ID: 18850763
[TBL] [Abstract][Full Text] [Related]
16. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Wu B; Li T; Chen H; Shen J
Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
[TBL] [Abstract][Full Text] [Related]
18. Using a population-based approach to prevent hepatocellular cancer in New South Wales, Australia: effects on health services utilisation.
Robotin MC; Kansil MQ; George J; Howard K; Tipper S; Levy M; Phung N; Penman AG
BMC Health Serv Res; 2010 Jul; 10():215. PubMed ID: 20663140
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
[No Abstract] [Full Text] [Related]
20. Disease burden of chronic hepatitis B among immigrants in Canada.
Wong WW; Woo G; Heathcote EJ; Krahn M
Can J Gastroenterol; 2013 Mar; 27(3):137-47. PubMed ID: 23516678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
